These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 2721530)

  • 1. Effective treatment of chronically progressive multiple sclerosis with low-dose cyclophosphamide with minor side-effects.
    Mauch E; Kornhuber HH; Pfrommer U; Hähnel A; Laufen H; Krapf H
    Eur Arch Psychiatry Neurol Sci; 1989; 238(3):115-7. PubMed ID: 2721530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mitoxantrone: a review of its use in multiple sclerosis.
    Scott LJ; Figgitt DP
    CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
    Hauser SL; Dawson DM; Lehrich JR; Beal MF; Kevy SV; Propper RD; Mills JA; Weiner HL
    N Engl J Med; 1983 Jan; 308(4):173-80. PubMed ID: 6294517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclophosphamide as second-line therapy in multiple sclerosis: benefits and risks.
    Rinaldi L; Perini P; Calabrese M; Gallo P
    Neurol Sci; 2009 Oct; 30 Suppl 2():S171-3. PubMed ID: 19882369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Evaluation of the results of treating progressive multiple sclerosis with cyclophosphamide].
    Wajgt A; Szyrocka-Szwed K; Gadomska B; Szczechowski L
    Neurol Neurochir Pol; 1988; 22(6):518-23. PubMed ID: 3077433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis.
    Gladstone DE; Zamkoff KW; Krupp L; Peyster R; Sibony P; Christodoulou C; Locher E; Coyle PK
    Arch Neurol; 2006 Oct; 63(10):1388-93. PubMed ID: 16908728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pulse-dose cyclophosphamide therapy for chronic progressive multiple sclerosis].
    Watanabe T; Yamamoto T; Saito T; Sugano M; Tsukamoto T
    Rinsho Shinkeigaku; 1993 Jan; 33(1):15-20. PubMed ID: 8334769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclophosphamide in relapsing remitting multiple sclerosis.
    D'Andrea F; D'Aurizio C; Marini C; Prencipe M
    Ital J Neurol Sci; 1990 Jun; 11(3):271-4. PubMed ID: 2387697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune deviation following pulse cyclophosphamide/methylprednisolone treatment of multiple sclerosis: increased interleukin-4 production and associated eosinophilia.
    Smith DR; Balashov KE; Hafler DA; Khoury SJ; Weiner HL
    Ann Neurol; 1997 Sep; 42(3):313-8. PubMed ID: 9307252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclophosphamide in chronic progressive multiple sclerosis. Maintenance vs nonmaintenance therapy.
    Goodkin DE; Plencner S; Palmer-Saxerud J; Teetzen M; Hertsgaard D
    Arch Neurol; 1987 Aug; 44(8):823-7. PubMed ID: 2820359
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated interleukin-12 in progressive multiple sclerosis correlates with disease activity and is normalized by pulse cyclophosphamide therapy.
    Comabella M; Balashov K; Issazadeh S; Smith D; Weiner HL; Khoury SJ
    J Clin Invest; 1998 Aug; 102(4):671-8. PubMed ID: 9710434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Early results of the treatment of chronic progressive forms of multiple sclerosis with cyclophosphamide and ACTH].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1988; 22(5):399-403. PubMed ID: 2854886
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclophosphamide for multiple sclerosis.
    La Mantia L; Milanese C; Mascoli N; Incorvaia B; D'Amico R; Weinstock-Guttman B
    Cochrane Database Syst Rev; 2002; (4):CD002819. PubMed ID: 12519578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].
    Mesaros S; Stojsavljević N; Dujmović I; Mandić E; Drulović J
    Srp Arh Celok Lek; 2004; 132(7-8):209-13. PubMed ID: 15615176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic effects of cyclophosphamide/ACTH in patients with chronic progressive multiple sclerosis.
    Hafler DA; Orav J; Gertz R; Stazzone L; Weiner HL
    J Neuroimmunol; 1991 May; 32(2):149-58. PubMed ID: 1672870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunosuppression in progressive multiple sclerosis with high dose intravenous cyclophosphamide and monoclonal antibodies.
    Dawson DM; Carter JL; Hafler DA; Weiner HL
    Riv Neurol; 1987; 57(2):88-91. PubMed ID: 3039645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate-dose versus low-dose cyclophosphamide and granulocyte colony-stimulating factor for peripheral blood stem cell mobilization in patients with multiple myeloma treated with novel induction therapies.
    Hamadani M; Kochuparambil ST; Osman S; Cumpston A; Leadmon S; Bunner P; Watkins K; Morrison D; Speir E; Deremer D; Kota V; Jillella A; Craig M; Awan F
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1128-35. PubMed ID: 22248715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cumulative experience with high-dose intravenous cyclophosphamide and ACTH therapy in chronic progressive multiple sclerosis.
    Carter JL; Dawson DM; Hafler DA; Fallis RJ; Stazzone L; Orav J; Weiner HL
    Ann N Y Acad Sci; 1988; 540():535-6. PubMed ID: 2849902
    [No Abstract]   [Full Text] [Related]  

  • 19. [Late results of the treatment of the chronic progressive form of multiple sclerosis by intensive immunosuppression].
    Wender M; Tokarz-Kupczyk E; Mularek O
    Neurol Neurochir Pol; 1989; 23(3):188-92. PubMed ID: 2561379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide cardiotoxicity in bone marrow transplantation: a prospective evaluation of new dosing regimens.
    Braverman AC; Antin JH; Plappert MT; Cook EF; Lee RT
    J Clin Oncol; 1991 Jul; 9(7):1215-23. PubMed ID: 2045862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.